Current concepts and review of alefacept in the treatment of psoriasis

Dermatologic Clinics

Volumn 22, Issue 4, 2004, Pages 407-426

  Krueger, Gerald G ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RETINOID DERIVATIVE;

ABSCESS; ANXIETY DISORDER; APPENDICITIS; ARTHRITIS; ASTHMA; B CELL LYMPHOMA; BACTERIAL INFECTION; BRAIN TUMOR; BRONCHITIS; BURN INFECTION; CELLULITIS; CHOLELITHIASIS; CLINICAL TRIAL; COLON POLYP; CONTACT DERMATITIS; CORRELATION ANALYSIS; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; ESOPHAGUS CARCINOMA; FLU LIKE SYNDROME; FOLLOW UP; GASTROENTERITIS; GOUT; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INFECTION RISK; INJECTION PAIN; INSOMNIA; KIDNEY CARCINOMA; LUNG CARCINOMA; LYMPHOMA; MELANOMA; MEMORY CELL; MYALGIA; NEPHROLITHIASIS; NONHODGKIN LYMPHOMA; PARESTHESIA; PHARYNGITIS; PHOTOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PRURITUS; PSORIASIS; PUVA; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT; SKIN CARCINOMA; TARGET CELL; TESTIS CANCER; TREATMENT WITHDRAWAL; WITHDRAWAL SYNDROME; WOUND INFECTION;

BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE; MAXIMUM TOLERATED DOSE; PROGNOSIS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4344659419     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2004.03.014     Document Type: Review

References (53)

1. Frampton J., Wagstaff A. Alefacept. Am J Clin Dermatol. 4(4):2003;277-286
2. Gordon K.B., McCormick T.S. Evolution of biologic therapies for the treatment of psoriasis. SKINmed: Dermatol Clinician. 2:2003;286-294
3. Gottlieb A.B., Bos J.D. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol. 105(2):2002;105-116
4. Krueger G.G. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther. 2(4):2002;431-441
5. Prinz J.C. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol. 17(3):2003;257-270
6. + human T cells. Eur J Immunol. 33(3):2003;666-675
7. Majeau G.R., Whitty A., Yim K., Meier W., Hochman P.S. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation. Cell Adhes Commun. 7(3):1999;267-279
8. Sanders M.E., Makgoba M.W., Sharrow S.O., Stephany D., Springer T.A., Young H.A., et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol. 140(5):1988;1401-1407
9. Majeau G.R., Meier W., Jimmo B., Kioussis D., Hochman P.S. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 152(6):1994;2753-2767
10. Miller G.T., Hochman P.S., Meier W., Tizard R., Bixler S.A., Rosa M.D., et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 178(1):1993;211-222
11. + cells. J Immunol. 168(9):2002;4462-4471
12. Ellis C.N., Krueger G.G. for the Alefacept Clinical Study Group Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 345:2001;248-255
13. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., Ellis C.N. for the Alefacept Clinical Study Group A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 47(6):2002;821-833
14. Lebwohl M., Christophers E., Langley R., Ortonne J.-P., Roberts J., Griffiths C.E.M. for the Alefacept Clinical Study Group An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 139:2003;719-727
15. Langley R., Christophers E., Lebwohl M. Efficacy and safety of multiple courses of intramuscular alefacept in patients with chronic plaque psoriasis [abstract]. J Invest Dermatol. 119:2002;344
16. Fredriksson T., Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 157(4):1978;238-244
17. Vaishnaw A.K., Ticho B. Alefacept is efficacious in a broad spectrum of patients with psoriasis, including those with severe disease. Presented at the 61st Annual Meeting of the American Academy of Dermatology. San Francisco, March 21-26, 2003
18. van de Kerkhof P., Vaishnaw A.K., Kragballe K., Ortonne J.-P. Alefacept is efficacious in a broad spectrum of patients with psoriasis. J Eur Acad Dermatol Venereol. 17(Suppl 1):2003;55
19. Christophers E., O'Gorman J., Vaishnaw A.K. Pooled efficacy of alefacept in psoriasis patients who are refractory or have contraindications to other psoriasis systemic treatments or phototherapies. Presented at the Ninth International Psoriasis Symposium. New York, June 18-22, 2003
20. Gordon K.B., Langley R.G. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2:2003;624-628
21. Gordon K.B., Vaishnaw A., O'Gorman J., Haney J., Menter A. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 139:2003;1563-1570
22. Ortonne J.-P., Lebwohl M., Griffiths C.E.M. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol. 13(2):2003;117-123
23. Chamian F., Novitskaya I., Khatcherian I., Gilleaudeau P., Sullivan-Whalen M., Lee E., et al. Therapeutic improvement induced by alefacept is linked to selective elimination of CD3+, CD8+ and CD103+ T cells from skin lesions of psoriasis vulgaris [abstract 88]. Br J Dermatol. 147:2002;1077-1078
24. Vaishnaw A.K., Lee S. Concomitant use of alefacept and immunosuppressants in patients with psoriasis. Presented at the 61st Annual Meeting of the American Academy of Dermatology. San Francisco, March 21-26, 2003
25. Lebwohl M., Vaishnaw A.K. Variability in circulating T-cell subsets among alefacept-treated and placebo-treated patients with psoriasis. Presented at Academy '03. Chicago, July 25-29, 2003
26. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 137(3):2001;280-284
27. Salonen S.H., for the EUROPSO Patient Survey Study Group. The EUROPSO psoriasis patient survey: first results from 17,990 association members with psoriasis. Presented at the Ninth International Psoriasis Symposium. New York, June 18-22, 2003
28. Salonen S.H., for the EUROPSO Patient Survey Study Group. The EUROPSO psoriasis patient survey: treatment history and satisfaction. Presented at the Ninth International Psoriasis Symposium. New York, June 18-22, 2003
29. O'Gorman J., Vaishnaw A. Lack of correlation between the quality of life (QOL) of psoriasis patients and objective measures of disease severity: an integrated analysis of phase 3 studies. Presented at Academy '03. Chicago, July 25-29, 2003
30. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 19(3):1994;210-216
31. Ellis C.N., Mordin M.M., Adler E.Y. Effects of alefacept on health-related quality of life in patients with psoriasis. Results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 4(2):2003;131-139
32. Feldman S.R., Menter A., Koo J.Y. Improved health-related quality of life following alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 150:2004;317-326
33. Finlay A.Y., Salek M.S., Haney J. for the Alefacept Clinical Study Group Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 206(4):2003;307-315
34. Carlin C.S., Feldman S.R., Krueger J.G., Menter A., Krueger G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Amer Acad Dermatol. 50:2004;859-866
35. Callis K.P., Chahda A., Vaishnaw A., Krueger G.G. Reduction of CD45RO+ effector T lymphocytes is not observed in the treatment of psoriasis with methotrexate [abstract]. J Invest Dermatol. 119:2002;244
36. Lee S. Safety of alefacept in patients who are refractory or have contraindications to other psoriasis therapies: pooled results of phase 3 studies. Presented at Academy '03. Chicago, July 25-29, 2003
37. Margolis D., Bilker W., Hennessy S., Vittorio C., Santanna J., Strom B.L. The risk of malignancy associated with psoriasis. Arch Dermatol. 137(6):2001;778-783
38. Mariette X., Cazals-Hatem D., Warszawki J., Liote F., Balandraud N., Sibilia J, and the investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15
39. + T-cell-directed antibody responses are maintained in psoriatic patients receiving alefacept: results of a randomized study. J Am Acad Dermatol. 49:2003;816-825
40. Fogelman I., Davey V., Ochs H.D., Elashoff M., Feinberg M.B., Mican J., et al. Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis. 182(2):2000;435-441
41. Ochs H.D., Davis S.D., Wedgwood R.J. Immunologic responses to bacteriophage φX 174 in immunodeficiency diseases. J Clin Invest. 50(12):1971;2559-2568
42. Pyun K.H., Ochs H.D., Wedgwood R.J., Xiqiang Y., Heller S.R., Reimer C.B. Human antibody responses to bacteriophage φX174: sequential induction of IgM and IgG subclass antibody. Clin Immunol Immunopathol. 51(2):1989;252-263
43. Rubinstein A., Mizrachi Y., Bernstein L., Shliozberg J., Golodner M., Liu G.-Q., et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage φX174 in asymptomatic HIV-1 infected patients. AIDS. 14(4):2000;F55-F62
44. Sullivan J.L., Ochs H.D., Schiffman G., Hammerschlag M.R., Miser J., Vichinsky E., et al. Immune response after splenectomy. Lancet. 1(8057):1978;178-181
45. Ortonne J.-P., Khemis A. A study of combination therapy with alefacept and ultraviolet B light for treatment of psoriasis [abstract 79]. Br J Dermatol. 147:2002;1075
46. Koo J.Y.M. Combination therapy with alefacept plus broadband ultraviolet B light for treatment of psoriasis. Presented at the Ninth International Psoriasis Symposium. New York, June 18-22, 2003
47. Krueger G.G., Gordon K., van de Kerkhof P., Sterry W. Repeated courses of IM alefacept in psoriasis: rationale and design of an international study that mimics the clinical practice setting. J Invest Dermatol. 121:2003;218. [abstract #339]
48. Costello P.J., Winchester R.J., Curran S.A., Peterson K.S., Kane D.J., Bresnihan B., et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol. 166(4):2001;2878-2886
49. Partsch G., Wagner E., Leeb B.F., Broll H., Dunky A., Smolen J.S. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis. 57(11):1998;691-693
50. Tassiulas I., Duncan S.R., Centola M., Theofilopoulos A.N., Boumpas D.T. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 60(6):1999;479-491
51. Kraan M.C., van Kuijk A.W.R., Dinant H.J., Goedkoop A.Y., Smeets T.J.M., de Rie M.E., et al. Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 46(10):2002;2776-2784
52. Smith J.B., Haynes M.K. Rheumatoid arthritis - a molecular understanding. Ann Intern Med. 136(12):2002;908-922
53. Schneider M., Stahl H.-D., Vaishnaw A., Podrebarac T., Juergen B. A pilot study of the safety and efficacy of alefacept in subjects with active rheumatoid arthritis on methotrexate [abstract OP0111]. Presented at the Fourth Annual European Congress of Rheumatology. Lisbon, Portugal, June 18-21, 2003 [abstract available at: http://www.eular.org. Accessed May 2003]